Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Long-Term Investments (2021)

Aligos Therapeutics filings provide 1 years of Long-Term Investments readings, the most recent being $15.1 million for Q4 2021.

  • On a quarterly basis, Long-Term Investments changed N/A to $15.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $15.1 million, a N/A change, with the full-year FY2021 number at $15.1 million, changed N/A from a year prior.
  • Long-Term Investments hit $15.1 million in Q4 2021 for Aligos Therapeutics, up from $492000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $15.1 million in Q4 2021 to a low of $492000.0 in Q3 2021.